BP
ONC

Ballentine Partners’s BeOne Medicines Ltd ONC Stock Holding History

Ballentine Partners’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$282K Buy
988
+82
+9% +$24.2K ﹤0.01% 825
2026
Q1 		$269K Buy
906
+28
+3% +$9.06K ﹤0.01% 795
2025
Q4 		$267K Buy
878
+126
+17% +$41.2K ﹤0.01% 769
2025
Q3 		$256K Buy
+752
New +$228K ﹤0.01% 801

Other funds holding ONC

CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
WAS
WESPAC Advisors SoCal Pasadena, California $560M AUM 37.11% 1-Year Est. Return
PFA
Peak Financial Advisors Denver, Colorado $242M AUM 19.63% 1-Year Est. Return
CST
Charles Schwab Trust Henderson, Nevada $1.79B AUM 17.47% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
SOAM
SBI Okasan Asset Management Tokyo, Japan $3.04B AUM
JGGDR
JGP Global Gestao de Recursos Rio De Janeiro, Brazil $45.3M AUM 42.75% 1-Year Est. Return
VWM
Venturi Wealth Management Austin, Texas $2.58B AUM 41.25% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
S
Steadtrust Allen, Texas $198M AUM 99.37% 1-Year Est. Return

Ballentine Partners's ONC Position: Q2 2026 in Review

Ballentine Partners increased its BeOne Medicines Ltd (ONC) stake by 9.1% in Q2 2026, buying an estimated $24.2K and bringing the position to 988 shares worth $282K. The position accounts for ﹤0.01% of the portfolio, ranked #825.

Ballentine Partners first reported a position in ONC in Q3 2025 and has held it in 4 quarters since. 31 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • Ballentine Partners held 988 shares of BeOne Medicines Ltd worth $282K as of Q2 2026.
  • Ballentine Partners bought 82 BeOne Medicines Ltd shares in Q2 2026, an estimated $24.2K.
  • BeOne Medicines Ltd made up ﹤0.01% of Ballentine Partners's portfolio in Q2 2026, its #825 holding.
  • Ballentine Partners first reported a position in BeOne Medicines Ltd in Q3 2025 and has held it in 4 quarters since.
  • 31 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.